This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

This database contains 63 studies, archived under the term: "France"

Click here to filter this large number of results.

Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders
Background: Immunization of patients with Alzheimer’s disease (AD) with synthetic amyloid-beta peptide (Abeta(42)) (AN1792) was previously studied in a randomized, double-blind, placebo-controlled phase 2a clinical trial, Study AN1792(QS-21)-201. Treatment was discontinued following reports of encephalitis. One year follow-up revealed that AN1792 antibody responders showed improvements in cognitive measures as assessed by the neuropsychological test battery […]

Early detection of memory impairment in people over 65 years old consulting at Health Examination Centers for the French health insurance: the EVATEM protocol
Background: Only half of those living with Alzheimer’s disease in France are currently diagnosed, and only one patient in three is supported during the early stages of dementia. This study aims to evaluate three cognitive tests for their predictive ability to diagnose mild cognitive impairments and Alzheimer’s disease and related disorders. For people aged 65 […]

Alzheimer’s disease–input of vitamin D with mEmantine assay (AD-IDEA trial): study protocol for a randomized controlled trial
Background: Current treatments for Alzheimer’s disease and related disorders (ADRD) are symptomatic and can only temporarily slow down ADRD. Future possibilities of care rely on multi-target drugs therapies that address simultaneously several pathophysiological processes leading to neurodegeneration. We hypothesized that the combination of memantine with vitamin D could be neuroprotective in ADRD, thereby limiting neuronal […]

Early detection of patients in the pre demented stage of Alzheimer’s disease: the Pre-Al Study
Objectives: The aim of the Pre-Al study is to evaluate and compare the predictive value of different tools for an early identification of Alzheimer’s disease.; Design and Participants: Patients coming for consultation to memory clinics without dementia were included if they had an objective memory or attention trouble assessed by a MMSE score > 25 […]

A follow‐up intervention in severely demented patients after discharge from a special Alzheimer acute care unit: Impact on early emergency room re‐hospitalization rate
Background: Emergency room (ER) re-hospitalizations are prevalent in severe Alzheimer’s disease affected older patients. Design: Quasi-experimental before and after study. Setting: Discharge of severely demented patients from a Special Alzheimer Acute Care Unit. Participants: A total of 390 patients hospitalized in the unit from 2007 through 2009, with at least one of the following characteristics: […]

Impact of a therapeutic educational program on quality of life in Alzheimer’s disease: Results of a pilot study
Background: Therapeutic patient education is expanding in the field of Alzheimer’s disease (AD). Objective: To evaluate the impact of a therapeutic educational program, on AD-affected patients and their caregivers, living in the community, on the patient’s quality of life. Methods: Non experimental before and after study. Patient/caregiver dyads were recruited in the geriatric department of […]

Memantine in behavioral variant frontotemporal dementia: negative results
We tested the efficacy and tolerability of one-year treatment with memantine (10 mg bid) in behavioral variant frontotemporal dementia (bvFTD). BvFTD patients aged 45 to 75 years, with a Mini-Mental Status Examination (MMSE) score ≥19, were enrolled in a national, randomized, double-blind, placebo-controlled (DBPC), Phase II trial. The primary endpoint was the CIBIC-Plus (Clinician’s Interview-Based […]

EHT0202 in Alzheimer’s disease: a 3-month, randomized, placebo-controlled, double-blind study
Background: EHT0202 (etazolate hydrochloride) is a new compound exhibiting both potential disease-modifying and symptomatic treatment properties in Alzheimer’s Disease increasing alpha-secretase activity and sAPP alpha secretion, as well as acting as a GABA-A receptor modulator and as a PDE-4 inhibitor.; Methods: This pilot, randomized, double-blind, placebo-controlled, parallel group, multicentre, Phase IIA study was conducted in […]

Long-term use of standardised Ginkgo biloba extract for the prevention of Alzheimer’s disease (GuidAge): a randomised placebo-controlled trial
Background: Prevention strategies are urgently needed to tackle the growing burden of Alzheimer’s disease. We aimed to assess efficacy of long-term use of standardised ginkgo biloba extract for the reduction of incidence of Alzheimer’s disease in elderly adults with memory complaints.; Methods: In the randomised, parallel-group, double-blind, placebo-controlled GuidAge clinical trial, we enrolled adults aged […]

Treatment of sleep apnoea syndrome decreases cognitive decline in patients with Alzheimer’s disease
Background: It is essential to detect and then treat factors that aggravate Alzheimer’s disease (AD). Here, we sought to determine whether or not continuous positive airway pressure (CPAP) therapy for sleep apnoea syndrome (SAS) slows the rate of cognitive decline in mild-to-moderate AD patients.; Methods: Between January 2003 and June 2011, we included consecutive, mild-to-moderate […]

Try searching our database by another keyword...

To make a new query of the database, please enter your search terms below:

�

Contact Us